Study of CM512 in Healthy Subjects and Patients With Atopic Dermatitis

Summary

This is a randomized, double-blind, single/multiple dose escalation, placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of CM512 in healthy subjects and patients with moderate to severe atopic dermatitis.

Timeline

Start

2024-09-02

Primary completion

2025-08-26

Completion

2025-09-12

Outcome

Met primary endpoint

release “CM512治疗成人中重度特应性皮炎（AD）I期临床研究（研究代号：CM512-100001）达成全部研究终点。” keymedbio.com ↗

Publications

• Cheng Y, Liu Q, Li M, Xie Y, Men Y, He M, Wang H, Feng X, Zeng M, Zhang L, Chen B, Li J, Feng P. First-in-human, phase 1 study of CM512, a TSLP/IL-13 bispecific antibody, in healthy volunteers: safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity. Front Immunol. 2026 May 28;17:1811041. doi: 10.3389/fimmu.2026.1811041. eCollection 2026.

Drugs

Indications